NeOnc Technologies Holdings, Inc. filed a formal corporate presentation for use in upcoming investor meetings, highlighting its clinical-stage CNS oncology platforms. The filing includes a clinical update for the NEO100 Phase 2a study, reporting an additional patient response that increased the objective response rate from 8.3% to 12.5%.
Neonc Technologies Holdings CEO, President Amir F. Heshmatpour Buys $151K of Stock
Amir F. Heshmatpour, CEO, President, bought 30,000 shares of Neonc Technologies Holdings, Inc. at $5.02 a share, worth $151K in total on Nov 13, 2026. Shares held after the trade: 3,353,000 (+0.9%).
NeOnc Technologies announced that CEO Amir Heshmatpour purchased 80,000 shares of common stock in the open market, bringing his total 2026 personal investment to 271,000 shares. Additionally, the company received a Type B End-of-Phase meeting from the FDA scheduled for January 2027 to discuss an accelerated approval pathway for its brain cancer candidate, NEO100.
Neonc Technologies Holdings CMO Thomas C. Chen Buys $10K of Stock
Thomas C. Chen, CMO, bought 2,284 shares of Neonc Technologies Holdings, Inc. at $4.38 a share, worth $10K in total on Nov 10, 2026. Shares held after the trade: 29,519 (+8.4%).
Neonc Technologies Holdings CEO, President Amir F. Heshmatpour Buys $294K of Stock
Amir F. Heshmatpour, CEO, President, bought 70,000 shares of Neonc Technologies Holdings, Inc. at $4.00 to $4.49 a share (average $4.21) in 3 transactions, worth $294K in total between Nov 10, 2026 and Nov 11, 2026. Shares held after the trade: 3,333,000 (+0.3%).